Critical Limb Ischemia - Pipeline Insight, 2021
This report can be delivered to the clients within 3-5 business days
DelveInsight’s, “Critical Limb Ischemia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Critical Limb Ischemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Critical Limb Ischemia: Overview
Critical Limb Ischemia (CLI) is a chronic condition and the most serious form of peripheral arterial disease (PAD). It is a major global health problem with a high and growing incidence. Importantly CLI has currently, limited treatment options and has a severe impact on the patient’s quality of life. CLI results from a severe blockage of the arteries in the lower limbs Symptoms include severe burning pain in the feet or toes even at rest. Complications include ulcers in the legs and feet that do not heal and commonly lead to gangrene and for which amputation of the affected limb is the only treatment option. The global amputation rate is estimated at 25% within one year of diagnosis, but vary according to the severity of the condition with rates of 11% in patients with superficial ulcers and up to 83% in patients with gangrene. In addition to limb loss, CLI is associated with a high risk of cardiovascular events, including myocardial infarction, stroke and death. The mortality risk has been reported to be as high as 20-25% within one year of diagnosis and surpasses 50% at 5 years post-diagnosis.
'Critical Limb Ischemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Critical Limb Ischemia pipeline landscape is provided which includes the disease overview and Critical Limb Ischemia treatment guidelines. The assessment part of the report embraces, in depth Critical Limb Ischemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Critical Limb Ischemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Critical Limb Ischemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Critical Limb Ischemia Emerging Drugs
Further product details are provided in the report.
Critical Limb Ischemia: Therapeutic Assessment
This segment of the report provides insights about the different Critical Limb Ischemia drugs segregated based on following parameters that define the scope of the report, such as:
Critical Limb Ischemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Critical Limb Ischemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Critical Limb Ischemia drugs.
Critical Limb Ischemia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Critical Limb Ischemia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Critical Limb Ischemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Critical Limb Ischemia: Overview
Critical Limb Ischemia (CLI) is a chronic condition and the most serious form of peripheral arterial disease (PAD). It is a major global health problem with a high and growing incidence. Importantly CLI has currently, limited treatment options and has a severe impact on the patient’s quality of life. CLI results from a severe blockage of the arteries in the lower limbs Symptoms include severe burning pain in the feet or toes even at rest. Complications include ulcers in the legs and feet that do not heal and commonly lead to gangrene and for which amputation of the affected limb is the only treatment option. The global amputation rate is estimated at 25% within one year of diagnosis, but vary according to the severity of the condition with rates of 11% in patients with superficial ulcers and up to 83% in patients with gangrene. In addition to limb loss, CLI is associated with a high risk of cardiovascular events, including myocardial infarction, stroke and death. The mortality risk has been reported to be as high as 20-25% within one year of diagnosis and surpasses 50% at 5 years post-diagnosis.
'Critical Limb Ischemia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Critical Limb Ischemia pipeline landscape is provided which includes the disease overview and Critical Limb Ischemia treatment guidelines. The assessment part of the report embraces, in depth Critical Limb Ischemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Critical Limb Ischemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Critical Limb Ischemia R&D. The therapies under development are focused on novel approaches to treat/improve Critical Limb Ischemia.
This segment of the Critical Limb Ischemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Critical Limb Ischemia Emerging Drugs
- Emiplacel: Pluristem Therapeutics
- RJX: Reven Pharmaceuticals
Further product details are provided in the report.
Critical Limb Ischemia: Therapeutic Assessment
This segment of the report provides insights about the different Critical Limb Ischemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Critical Limb Ischemia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Critical Limb Ischemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Critical Limb Ischemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Critical Limb Ischemia drugs.
Critical Limb Ischemia Report Insights
- Critical Limb Ischemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Critical Limb Ischemia drugs?
- How many Critical Limb Ischemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Critical Limb Ischemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Critical Limb Ischemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Critical Limb Ischemia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Pluristem Therapeutics
- Reven Pharmaceuticals, Inc.
- New Beta Innovation Limited
- Libella Gene Therapeutics
- Lifecells, LLC.
- Helixmith
- Caladrius Biosciences, Inc.
- Beijing Northland Biotech. Co., Ltd.
- BioGenCell Ltd.
- Ixaka Ltd
- Anaeropharma Science
- Antidote Therapeutics
- Cynata Therapeutics Limited
- Gurus BioPharm LLC
- Hemostemix Inc.
- Juventas Therapeutics
- Rexgenero
- Symic Bio
- Ambulero, Inc.
- Emiplacel
- RJX
- YQ23
- JVS-100
- AAV-hTERT
- ASCT01
- VM202
- CLBS12
- NL003
- GUR-602
- Cymerus™ MSCs
- BGC101
- REX-001
- ATI-1013
- FGF2
- ACP-01
- SB-030
- AMB-201
Introduction
Executive Summary
Critical Limb Ischemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Critical Limb Ischemia – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Emiplacel: Pluristem Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
CLBS12: Caladrius Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
RJX: Reven Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Critical Limb Ischemia Key Companies
Critical Limb Ischemia Key Products
Critical Limb Ischemia- Unmet Needs
Critical Limb Ischemia- Market Drivers and Barriers
Critical Limb Ischemia- Future Perspectives and Conclusion
Critical Limb Ischemia Analyst Views
Critical Limb Ischemia Key Companies
Appendix
Executive Summary
Critical Limb Ischemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Critical Limb Ischemia – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Emiplacel: Pluristem Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
CLBS12: Caladrius Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I)
Comparative Analysis
RJX: Reven Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Critical Limb Ischemia Key Companies
Critical Limb Ischemia Key Products
Critical Limb Ischemia- Unmet Needs
Critical Limb Ischemia- Market Drivers and Barriers
Critical Limb Ischemia- Future Perspectives and Conclusion
Critical Limb Ischemia Analyst Views
Critical Limb Ischemia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Critical Limb Ischemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Critical Limb Ischemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Critical Limb Ischemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Critical Limb Ischemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
